Aileen T Nerio

6410219, Jun 25, 2002

Mar 30, 2000

09/539226

David Cook - Walnut Creek CA
Susan Wollowitz - Walnut Creek CA
Aileen Nerio - Santa Clara CA

Cerus Corporation - Concord CA

A01N 102

435 2, 435238, 514297

Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.

6455286, Sep 24, 2002

Feb 9, 2000

09/500680

Susan Wollowitz - Walnut Creek CA
Aileen Nerio - Fremont CA

Cerus Corporation - Concord CA

C12N 1300

4351733, 4351731, 4351737

Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4â and 5â derivatives of proralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.

6514987, Feb 4, 2003

Jul 2, 2000

09/610652

David Cook - Lexington MA
John E. Merritt - Walnut Creek CA
Aileen Nerio - Fremont CA
Henry Rapoport - Berkeley CA
Adonis Stassinopoulos - Dubin CA
Susan Wollowitz - Lafayette CA
Jan Matejovic - Toronto, CA
William A. Denny - Auckland, NZ

Cerus Corporation - Concord CA

A61K 3144

514297, 546102

Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

20020182581, Dec 5, 2002

Mar 12, 2002

10/096196

David Cook - Lafayette CA, US
Susan Wollowitz - Lafayette CA, US
Aileen Nerio - Fremont CA, US

Cerus Corporation - Concord CA

A01N001/02
C12N005/08

435/002000, 435/372000

Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.

20030082510, May 1, 2003

Jul 30, 2002

10/208583

Susan Wollowitz - Lafayette CA, US
Aileen Nerio - Fremont CA, US

Cerus Corporation - Concord CA

A01N001/02

435/002000

Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4′ and 5′ derivatives of psoralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.

20040029897, Feb 12, 2004

Jan 13, 2003

10/341917

David Cook - Lafayette CA, US
John Merritt - Walnut Creek CA, US
Aileen Nerio - Fremont CA, US
Henry Rapoport - Berkeley CA, US
Adonis Stassinopoulos - Dublin CA, US
Susan Wollowitz - Lafayette CA, US

Cerus Corporation - Concord CA

A61K031/497
A61K031/4433
A61K031/4025
A61K031/366
C07D493/02

514/255050, 514/338000, 514/422000, 514/455000, 544/405000, 546/283100, 548/525000, 549/282000

Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

60937254, Jul 25, 2000

Jan 6, 1998

9/003115

David Cook - Lafayette CA
John E. Merritt - Walnut Creek CA
Aileen Nerio - Fremont CA
Henry Rapoport - Berkeley CA
Adonis Stassinopoulos - Dublin CA
Susan Wollowitz - Walnut Creek CA
Jan Matejovic - Toronto, CA

Cerus Corporation - Concord CA

A61K 3144
C07D21908

514297

Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

58719008, Feb 16, 1999

Nov 7, 1997

8/966774

Susan Wollowitz - Walnut Creek CA
Stephen T. Isaacs - Orinda CA
Henry Rapoport - Berkeley CA
Hans Peter Spielmann - Berkeley CA
Aileen Nerio - Santa Clara CA

Cerus Corporation - Concord CA

A01N 102
C12N 706

435 2

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.